STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1/2-4	Title page/1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3/31-49	Abstract/1-4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	5-7/59-85	Introduction/1-3
Objectives	3	State specific objectives, including any prespecified hypotheses	6/81-84	Introduction/3
Methods				
Study design	4	Present key elements of study design early in the paper	7/89-104	Methods/1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7/89-104	Methods/1
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	7-9/92-141	Methods/1-4
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	9-10/149-156	Methods/5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9/132-141	Methods/4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	9/132-141	Methods/4
Bias	9	Describe any efforts to address potential sources of bias	9-10/149-156	Methods/5
Study size	10	Explain how the study size was arrived at	9-10/149-156	Methods/5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-10/144-149	Methods/5

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10/144-157	Methods/5
		(b) Describe any methods used to examine subgroups and interactions	9-10/144-157	Methods/5
		(c) Explain how missing data were addressed	7/99	Methods/1
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	7/99	Methods/1
		(e) Describe any sensitivity analyses	NA	NA
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10/160-166	Results/1 Figure 1
		(b) Give reasons for non-participation at each stage	10/160-166	Results/1
		(c) Consider use of a flow diagram	24/413	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10/170-171 21/391-395	Results/1 Table 1
		(b) Indicate number of participants with missing data for each variable of interest	NA	NA
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	10/160-162	Results/1
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	10-11/172-178	Results/2
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	NA	NA
		Cross-sectional study—Report numbers of outcome events or summary measures	NA	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	22/398-403	Table 2
		(b) Report category boundaries when continuous variables were categorized	21-22/391-403	Table 1, 2
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA	NA
Discussion				
Key results	18	Summarise key results with reference to study objectives	11-12/193-197	Discussion/2
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14/249-256	Discussion/5

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14/181-256	Discussion/1-5
Generalisability	21	Discuss the generalisability (external validity) of the study results	14/249-260	Discussion/5
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15/264	Acknowledgment

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/jtd-23-1667
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.